{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:33:12Z","timestamp":1772137992712,"version":"3.50.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Traditional treatments for obstructive hypertrophic cardiomyopathy (oHCM) include \u03b2-blockers, calcium channel blockers, and disopyramide. Mavacamten, a novel cardiac myosin inhibitor, is a promising oHCM therapy but has practical challenges limiting its use. This descriptive study aimed to describe a clinic workflow for mavacamten management in a real-world setting, addressing challenges such as cost, drug interactions, and monitoring requirements. The focus was on reducing patient-level costs while ensuring feasibility and efficiency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 34 patients with oHCM for whom mavacamten was considered between May 2022 and May 2023. The clinic workflow involved cardiologist assessment, pharmacist evaluation of drug interactions, enrollment in the mavacamten risk evaluation and mitigation strategy program, cost reduction measures, and initiation of monitoring through scheduled echocardiograms. Of the 34 patients, 21 (62%) were initiated on mavacamten and followed for up to 1 year on therapy. The median time from referral to prior authorization approval and first fill was 5 and 22 days, respectively. Patients demonstrated high adherence (99.1%) as measured by the proportion of days covered. Echocardiogram follow-up showed improvements in left ventricular outflow tract parameters with no patients having a decrease in left ventricular ejection fraction to less than 50%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The described workflow effectively addressed challenges associated with mavacamten management, emphasizing roles for clinic personnel, cost reduction strategies, and structured patient monitoring. While the workflow\u2019s specifics may need adaptation in different settings, this report provides valuable insights for clinics implementing structured mavacamten management approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae372","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T23:26:10Z","timestamp":1732749970000},"page":"e383-e389","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of a multidisciplinary approach to management of mavacamten in obstructive hypertrophic cardiomyopathy"],"prefix":"10.1093","volume":"82","author":[{"given":"Hanna","family":"Jensen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, UC San Diego Health , San Diego, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaid","family":"Yousif","sequence":"additional","affiliation":[{"name":"UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences , La Jolla, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trina","family":"Huynh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UC San Diego Health , San Diego, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Kraushaar","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, UC San Diego Health , San Diego, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcy","family":"Reed","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, UC San Diego Health , San Diego, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trista","family":"Boarman","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, UC San Diego Health , San Diego, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Silva","family":"Enciso","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, UC San Diego Health , San Diego, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Willeford","sequence":"additional","affiliation":[{"name":"UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences , La Jolla, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"issue":"12","key":"2025042510164834700_CIT0001","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"10075","key":"2025042510164834700_CIT0002","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(16)31321-6","article-title":"Hypertrophic obstructive cardiomyopathy","volume":"389","author":"Veselka","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"2025042510164834700_CIT0003","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","article-title":"Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC State-of-the-Art Review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"2025042510164834700_CIT0004","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"issue":"4","key":"2025042510164834700_CIT0005","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cardfail.2014.01.014","article-title":"Latent obstruction and left atrial size are predictors of clinical deterioration leading to septal reduction in hypertrophic cardiomyopathy","volume":"20","author":"Finocchiaro","year":"2014","journal-title":"J Card Fail"},{"issue":"5","key":"2025042510164834700_CIT0006","doi-asserted-by":"publisher","first-page":"e006657","DOI":"10.1161\/JAHA.117.006657","article-title":"Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy","volume":"7","author":"Lu","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2025042510164834700_CIT0007","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1055\/s-0039-1678724","article-title":"Atrial fibrillation and stroke in patients with hypertrophic cardiomyopathy: important new insights","volume":"119","author":"Borer","year":"2019","journal-title":"Thromb Haemost"},{"issue":"4","key":"2025042510164834700_CIT0008","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12265-009-9147-0","article-title":"Sudden death in hypertrophic cardiomyopathy","volume":"2","author":"Maron","year":"2009","journal-title":"J Cardiovasc Transl Res"},{"issue":"37","key":"2025042510164834700_CIT0009","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"issue":"23","key":"2025042510164834700_CIT0010","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"issue":"30","key":"2025042510164834700_CIT0011","doi-asserted-by":"publisher","first-page":"eabo7622","DOI":"10.1126\/sciadv.abo7622","article-title":"Mavacamten, a precision medicine for hypertrophic cardiomyopathy: from a motor protein to patients","volume":"9","author":"Nag","year":"2023","journal-title":"Sci Adv"},{"issue":"10253","key":"2025042510164834700_CIT0012","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"2025042510164834700_CIT0013","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2025042510164834700_CIT0014","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40265-022-01739-7","article-title":"Mavacamten: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"2025042510164834700_CIT0015","volume-title":"Application Number 214998Orig1s000: Mavacamten Clinical Pharmacology and Biopharmaceutics Review.","author":"Center for Drug Evaluation and Research","year":"2021"},{"key":"2025042510164834700_CIT0016","volume-title":"Package insert","author":"Camzyos (mavacamten)","year":"2024"},{"key":"2025042510164834700_CIT0017","article-title":"FDA approves Bristol Myers\u2019 oral heart disease drug","year":"2022","journal-title":"Reuters"},{"key":"2025042510164834700_CIT0018","author":"Bristol Myers Squibb"},{"key":"2025042510164834700_CIT0019","volume-title":"Camzyos REMS patient brochure","author":"Bristol Myers Squibb"},{"key":"2025042510164834700_CIT0020","author":"Bristol Myers Squibb"},{"key":"2025042510164834700_CIT0021","author":"HealthWell Foundation"},{"issue":"12","key":"2025042510164834700_CIT0022","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/phar.2874","article-title":"Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: a case series and clinical guide","volume":"43","author":"Willeford","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2025042510164834700_CIT0023","author":"Willeford"},{"key":"2025042510164834700_CIT0024","author":"University of Calgary"},{"key":"2025042510164834700_CIT0025","volume-title":"2024 Medicare-Medicaid Plan Performance Data Technical Notes.","author":"Centers for Medicare and Medicaid Services"},{"key":"2025042510164834700_CIT0026","author":"Pharmacy Quality Alliance"},{"key":"2025042510164834700_CIT0027","author":"Bristol Myers Squibb"},{"issue":"10","key":"2025042510164834700_CIT0028","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.18553\/jmcp.2016.22.10.1167","article-title":"Impact of pharmacy intervention on prior authorization success and efficiency at a university medical center","volume":"22","author":"Cutler","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"2025042510164834700_CIT0029","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1200\/JOP.2016.017756","article-title":"Prior authorization for medications in a breast oncology practice: navigation of a complex process","volume":"13","author":"Agarwal","year":"2017","journal-title":"J Oncol Pract"},{"key":"2025042510164834700_CIT0030","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3389\/fphar.2018.01290","article-title":"A systematic review of medication adherence thresholds dependent of clinical outcomes","volume":"9","author":"Baumgartner","year":"2018","journal-title":"Front Pharmacol"},{"issue":"13","key":"2025042510164834700_CIT0031","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1056\/NEJMp1301993","article-title":"Prescription-drug coupons\u2014no such thing as a free lunch","volume":"369","author":"Ross","year":"2013","journal-title":"N Engl J Med"},{"issue":"21","key":"2025042510164834700_CIT0032","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMp1607378","article-title":"Undermining value-based purchasing\u2014lessons from the pharmaceutical industry","volume":"375","author":"Dafny","year":"2016","journal-title":"N Engl J Med"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae372\/60990839\/zxae372.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/7\/e383\/62974614\/zxae372.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/7\/e383\/62974614\/zxae372.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:16:52Z","timestamp":1745576212000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/7\/e383\/7913356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,11,29]]},"published-print":{"date-parts":[[2025,4,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae372","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.03.05.24303837","asserted-by":"object"}]},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4,1]]},"published":{"date-parts":[[2024,11,29]]}}}